
Taking a closer look at the Most Favored Nation Pricing Executive Order
PwC specialists break down MFN drug pricing and what companies should do now to reassess pricing, supply chains, and policy risks.
Co-hosted by Glenn Hunzinger, US Health Industries leader, and Jennifer Colapietro, Consulting Commercial Leader, the Next in Health podcast series offers insights on the most important issues facing pharma, medtech and healthcare. PwC business leaders discuss the latest trends and their impact on health industries, whether it’s policy, AI, innovation, care delivery, business model reinvention or bold moves for the future. If it’s happening in health industries, we’re talking about it.
Listen in to PwC Next in Health podcast conversations here or follow our series Apple Podcasts, Spotify, YouTube Music and more.
PwC specialists break down MFN drug pricing and what companies should do now to reassess pricing, supply chains, and policy risks.
Explore how pharma and biotech leaders can navigate FDA disruption with smarter submissions, regulatory agility, and global risk mitigation strategies.
Explore the rise of China’s biotech industry and what it means for U.S. pharma, from innovation and partnerships to diligence and global strategy.
Explore how shifting policies, tariffs, AI, and regulatory changes are reshaping healthcare strategy, innovation, and affordability in 2025.